Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2003-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effectiveness of TLK286 in the treatment of advanced non-small cell lung cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Telik

Criteria

Inclusion Criteria:

• Histologic or cytologic diagnosis of non-small cell lung carcinoma

• Progressed while on or after treatment on platinum-based regimen

• Patients may not have had more than one prior cytotoxic chemotherapy regimen

• Stage IV or IIIB

• Age at least 18 years

• Adequate liver and kidney function

• Adequate bone marrow function

Exclusion Criteria:

• Pregnancy or lactation

• Unstable medical conditions

• Chemotherapy, hormonal therapy, radiotherapy, radiopharmaceuticals or immunotherapy within 3 weeks of TLK286

• CNS metastasis unless controlled by treatment